ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-EGFR Antibody-drug Conjugate CPO301

Also written as “SYS6010”, “SYS6010 injection” and “SYS6010 combined with Enlonstobart”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Squamous Cell Carcinoma of Head and Neck · Breast Neoplasms · Nasopharyngeal Carcinoma, led by 2 companies.

Drug pageAnti-EGFR Antibody-drug Conjugate CPO301: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 12, 202516 company-led studies, 16 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group1515 open or runningphase 3since Mar 12, 2025Jan 1, 2025Nov 30, 2026phase 2 · NCT07256509
Conjupro Biotherapeuticsits history only11 open or runningphase 1since Jun 22, 2023Jun 22, 2023May 2027phase 1 · NCT05948865
  • Named in CSPC Pharmaceutical Group’s own pipeline as SYS6010 (EGFR ADC), phase 3, as of Aug 20, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 1, 2025First study: phase 2 study in Breast NeoplasmsFirst studyNCT06775236 · 410 planned
  2. Mar 12, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06927986 · 380 planned · China
  3. Nov 13, 2025Phase 3 study in Esophageal Squamous Cell CarcinomaNCT07251062 · 737 planned
  4. Nov 18, 20252 phase 2 studiesNCT07254585, NCT07256509
  5. Jan 22, 20262 phase 3 studiesNCT07376382, NCT07406542
  6. Feb 4, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07472647 · 596 planned
  7. Feb 4, 20262 phase 3 studiesNCT07442565, NCT07417735
  8. May 31, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07633873 · 500 planned
  9. Jun 21, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07672223 · 586 planned · China
  10. Aug 6, 2026Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT07758621 · 340 planned
  11. Oct 19, 2026Primary completion moved from 2026-06-30 to 2028-06-30Date moved laterphase 2 · +24 months · NCT07254585
  12. Oct 25, 20262 phase 3 studiesNCT07925021, NCT07924111

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07256509
  2. Dec 12, 2026Primary completion: phase 3 study in NSCLCNCT07376382
  3. Jun 15, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06775236
  4. Sep 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07633873

TargetBeta

“An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-EGFR ADC CPO301, the monoclonal an…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1) ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 15 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07924111Esophageal Squamous Cell Carcinoma3Not yet recruitingDec 30, 2029585
NCT07925021Nasopharyngeal Carcinoma · China3RecruitingOct 1, 2029424
NCT07758621Squamous Cell Carcinoma of Head and Neck3Not yet recruitingSep 15, 2028340
NCT07672223Carcinoma, Non-Small-Cell Lung · China3RecruitingSep 30, 2029586
NCT07633873Carcinoma, Non-Small-Cell Lung3Not yet recruitingSep 30, 2027500
NCT07417735Locally Advanced/Metastatic/Recurrent ESCC3Not yet recruitingDec 31, 2028436
NCT07472647Carcinoma, Non-Small-Cell Lung2Not yet recruitingFeb 28, 2029596
NCT07442565Carcinoma, Non-Small-Cell Lung3Not yet recruitingDec 30, 2027506
NCT07406542Recurrence3Not yet recruitingApr 1, 2029400
NCT07376382NSCLC3Not yet recruitingDec 12, 2026680
NCT07256509Carcinoma, Non-Small-Cell Lung2Not yet recruitingNov 30, 2026120
NCT07254585Squamous Cell Carcinoma of Head and Neck · China2RecruitingJun 30, 2028110
NCT07251062Esophageal Squamous Cell Carcinoma3Not yet recruitingDec 30, 2029737
NCT06927986Carcinoma, Non-Small-Cell Lung · China3RecruitingJul 30, 2026380
NCT06775236Breast Neoplasms2Not yet recruitingJun 15, 2027410

How it is read

Names in the registry

  • “SYS6010”, 9 entries
  • “SYS6010 injection”, 2 entries
  • “SYS6010 combined with Enlonstobart”, 1 entry
  • “CPO301”, 1 entry
  • “SYS6090 + SYS6010”, 1 entry

Codes read as this program: SYS6010.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.